• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

EverlyWell Raises Additional Capital to Expand Convenient At-Home Health Testing

by Fred Pennic 05/03/2017 Leave a Comment

EverlyWell Convenient At-Home Health Testing

EverlyWell, an Austin, TX-based next-generation healthcare testing platform has completed another round of funding led by NextGen Venture Partners with Jack Novak, SoGal Ventures, Full Tilt Capital, including participation from other investors. The latest round brings the company’s total funding to $5 million since its inception in 2015.

EverlyWell offers a suite of regulatory-compliant, physician-reviewed, at-home lab tests, without a lab visit or an in-person doctor referral. The platform currently offers 12 different at-home lab tests including sexual health, thyroid, metabolism, men’s health, and breast milk DHA testing, which the company is the exclusive provider of in the U.S.

EverlyWell works with a physician network to ensure that each at-home lab test is authorized by a board-certified physician in the patient’s state and that their results are reviewed and released by a physician prior to receiving them. A customer selects and purchases a kit that arrives to their home, and he or she collects a sample via pinprick dried blood spot, saliva or urine and sends it to EverlyWell’s certified lab partners.

The lab results are then delivered online via a secure EverlyWell dashboard using infographics and detailed explanations that are easy for patients to share their results with healthcare providers, family and friends. Each lab test also comes with personalized recommendations depending on a customer’s results.

The digital health startup, led by EverlyWell’s CEO and founder, Julia Cheek, reached millions in sales less than a year after its beta launch — while also delivering profitable unit economics. The company now has 15 full-time employees and thousands of customers in 46 states.

 

“Our vision is to make healthcare services like lab testing accessible, simple, and meaningful for consumers. This additional funding enables us to accelerate our growth even more,” says Julia Cheek, CEO and Founder of EverlyWell in a statement. “We’re leading a major shift in the consumer health marketplace by bringing the lab to consumers’ doorsteps, and we are moving quickly to expand our channels, launch innovative tests, and deliver a world-class customer experience.”

Tagged With: At-Home Health Testing, EverlyWell

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |